Posaconazole: a new broad-spectrum antifungal agent.
Article Details
- CitationCopy to clipboard
Kwon DS, Mylonakis E
Posaconazole: a new broad-spectrum antifungal agent.
Expert Opin Pharmacother. 2007 Jun;8(8):1167-78.
- PubMed ID
- 17516880 [ View in PubMed]
- Abstract
The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical efficacy in the treatment of oropharyngeal candidiasis and has shown promise as salvage therapy for invasive aspergillosis, zygomycosis, cryptococcal meningitis and a variety of other fungal infections. In addition, data from randomized controlled studies support its efficacy for use in prophylaxis of invasive fungal infections in patients who are severely immunocompromised. The wide spectrum activity of posaconazole in in vitro studies, animal models and preliminary clinical studies suggest that posaconazole represents an important addition to the antifungal armamentarium.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Posaconazole Cytochrome P450 51 Protein Yeast YesAntagonistDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Posaconazole Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorDetails